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Objectives This observational study was requested by French health authorities to
determine the impact of lopinavir/ritonavir (Kaletra®) on antiretroviral resistance in
clinical practice. Virological failures of lopinavir/ritonavir and their effects on the
resistance to protease inhibitors and reverse transcriptase inhibitors were evaluated
in protease inhibitor-experienced patients.Patients and methods Virological failure
was defined as an HIV-1 plasma viral load >50 copies/mL after at least 3 months of
lopinavir/ritonavir-containing antiretroviral therapy. For all patients, a resistance
genotypic test was available at failure and before lopinavir/ritonavir treatment. Data
from 72 patients with inclusion criteria were studied. Results The mean viral load at
baseline was 4 log10 copies/mL (1.6–6.5). Mutations in the protease gene
significantly selected between baseline and failure were L10V, K20R, L33F, M36I,
I47V, I54V, A71V and I85V (P < 0.05). Patients who had more than seven protease
inhibitor mutations at baseline showed a significantly increased risk of occurrence of
protease inhibitor mutations. The proportion of viruses susceptible to atazanavir,
fosamprenavir and darunavir decreased significantly between baseline and failure (P
< 0.05). Among patients with a virus susceptible to atazanavir at day 0, 26% (n = 14)
exhibited a virus resistant or possibly resistant at the time of failure. This proportion
was 32% (n = 16) for fosamprenavir and 16% (n = 7) for darunavir. Conclusions A
darunavir-based regimen appears to be a sequential option in the case of
lopinavir/ritonavir failure. To compare and determine the best treatment sequencing,
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